2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working PartyMichael Heuser, Jacqueline Cloos, Sylvie Freeman et al.|Blood|2021Cited by 714
PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemiaZhaohui Gu, Williams E. Evans, Michelle L. Churchman et al.|Nature Genetics|2019Cited by 616
Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II StudyNaval Daver, Hagop M. Kantarjian, Guillermo Garcia‐Manero et al.|Cancer Discovery|2018Cited by 570
Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AMLZhihong Zeng, Marina Konopleva|Blood|2008Cited by 512
Ibrutinib and Venetoclax for First-Line Treatment of CLLNitin Jain, William G. Wierda, Michael J. Keating et al.|New England Journal of Medicine|2019Cited by 502